When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOV - Myovant Sciences announces distribution of ORGOVYX in the U.S.
Myovant Sciences Ltd.
Myovant Sciences ([[MYOV]] +0.9%) announced that ORGOVYX™ is approved by the U.S. FDA for the treatment of adult patients with advanced prostate cancer. “Myovant has been focused on ensuring access to ORGOVYX for men with advanced prostate cancer as quickly as possible following approval, and we are delighted to announce that it is now available,” said David Marek, CEO. ORGOVYX was approved by the FDA on Dec. 18, 2020 and is now available through authorized specialty distributors.